NEWS CENTER

NEWS CENTER

——

Company News
Industry News
The API market ushered in volume, and a large number of enterprises are accelerating the expansion of production capacity Article link: Pharmaceutical Network https://www.zyzhan.com/news/detail/81957.html

2021-09-01

The API market ushered in volume, and a large number of enterprises are accelerating the expansion of production capacity Article link: Pharmaceutical Network https://www.zyzhan.com/news/detail/81957.html

【Pharmaceutical Network Industry News】API refers to any substance or mixture of substances used in pharmaceutical manufacturing, and when used in pharmaceutical products, it becomes an active ingredient of drugs. In recent years, driven by aging and the expiration of patented drugs, the global generic drug market has begun to maintain high growth, which has also indirectly driven the development of the API market. Article link: Pharma.com https://www.zyzhan.com/news/detail/81957.html

The sword points to a $3 billion space! The development of BCL-2 is timely

2021-09-01

The sword points to a $3 billion space! The development of BCL-2 is timely

The B lymphocytoma-2 gene (Bcl-2) plays an important role in apoptosis and is one of the factors that cause hematologic tumors. At present, for the research and development of Bcl-2 target, AbbVie's Venetoclax has been listed in 2016, and domestic Ascentage Pharma, BeiGene, Fosun Pharma, etc. have also laid out this target. In this paper, by analyzing the layout of Bcl-2, we explore the future development direction of this target.

391 pharmaceutical companies posted their report cards in the first half of the year, and 18 had gross profit margins of more than 90%

2021-09-01

391 pharmaceutical companies posted their report cards in the first half of the year, and 18 had gross profit margins of more than 90%

Pharmaceutical Network on September 1 Up to now, a total of 391 A-share pharmaceutical companies have disclosed their performance in the first half of 2021, and more than seventy percent of the company's performance (revenue and net profit) have both risen.

Introduction of wholly-owned subsidiary - Deyang Rui and Dede Pharmaceutical Technology Co., Ltd

2021-08-24

Introduction of wholly-owned subsidiary - Deyang Rui and Dede Pharmaceutical Technology Co., Ltd

Deyang Rui Hede Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary, was officially established on March 29, 2021, and the company's factory in Deyang was officially started in March 2021, and it is planned to enter the trial stage within the year.

The official website of Chengdu Ruihede Pharmaceutical Technology Co., Ltd. is online!

2021-08-24

The official website of Chengdu Ruihede Pharmaceutical Technology Co., Ltd. is online!

The official website of Chengdu Ruihede Pharmaceutical Technology Co., Ltd. is online!

< 1 >

Service Hotline:

18183292809

Sales mailbox:

sales@ruihede.com

Address:

Floor 1-2, Building 13, No. 188, West Section of Kexing Road, Wenjiang District, Chengdu

Focus on us

Focus on us

COPYRIGHT©2023 RUIHEDE PHARMACEUTICAL TECHNOLOGY CO., LTD. ALL RIGHTS RESERVED.  POWER BY：300.cn·Chengdu

SAF Coolest v1.3 设置面板GFFSX-ZNIR-QVAFE-AAS

营业执照及SEO链接： Business License

无数据提示

Sorry, the current column has no content for the time being.!

You can view other columns or returnHome Page

SVG图标库请自行添加图标，用div包起来，并命名使用